Findings help investigators understand how FDA-approved AGN-19058 behaves

Conferences|ASCRS

George Waring, MD, discusses the findings of a retrospective study on Allergan’s AGN-190584 for the treatment of presbyopia.

Related Videos
Related Content

FDA approves twice-daily dosing option for presbyopia eye drop treatment

March 30th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

COPHy 2023: Traveling the path to new restorative therapies

March 24th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

FDA approves twice-daily dosing option for presbyopia eye drop treatment

March 30th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

COPHy 2023: Traveling the path to new restorative therapies

March 24th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

FDA approves twice-daily dosing option for presbyopia eye drop treatment

March 30th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

COPHy 2023: Traveling the path to new restorative therapies

March 24th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.